CGC

Canopy Growth Corp. (CGC) - Q2 2026 (Ended Sept 30, 2025) Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2025 (Q2 of Fiscal 2026). Canopy Growth Corporation is a global cannabis company operating primarily in Canada, Europe, and Australia, with a significant non-controlling interest in Canopy USA, LLC, which holds U.S. cannabis assets (including Acreage, Wana, and Jetty). The company reports in Canadian dollars (CAD) and has resolved previous going concern doubts due to improved liquidity.

Key Financial Metrics

Material Changes vs. Prior Period

• Significant Loss Reduction: Net loss from continuing operations improved dramatically year-over-year (down 99% for Q2 and 83% YTD). This is primarily driven by a $100.8M swing in "Other income (expense), net," turning a $85.3M expense in Q2 2024 into a $15.5M gain in Q2 2025.
• Fair Value Gains: The improvement in "Other income" was largely due to non-cash fair value increases in Canopy USA-related assets (specifically the Canopy USA LPs equity method investment), offset by decreases in the Elevate loan receivable valuation.
• Revenue Growth: Net revenue increased 6% QoQ and 7% YTD. Canadian adult-use cannabis revenue grew 30% QoQ, and medical cannabis grew 17% QoQ. International cannabis revenue declined 39% QoQ due to supply chain challenges in Europe.
• Debt Reduction: Total debt decreased by approximately $76M from the prior fiscal year-end due to significant paydowns on the Credit Facility and the full settlement of Supreme Debentures and Accretion Debentures.
• Cost Discipline: Operating expenses decreased 43% QoQ, driven by a 98% reduction in asset impairment/restructuring charges and a 62% drop in share-based compensation.

Guidance, Outlook, and Risks

• Liquidity Position: Management states that with $298.1M in cash and reduced debt, the company has sufficient liquidity to meet short-term obligations, resolving prior going concern uncertainties.
• Equity Financing: The company completed a $200M (US) ATM program in February 2025 and launched a new $200M (US) ATM program in August 2025. As of November 5, 2025, approximately $154.8M remains available under the new program.
• Canopy USA Strategy: The company continues to pursue U.S. market entry via Canopy USA. Canopy USA now owns 100% of Acreage Holdings. Canopy Growth holds non-voting shares in Canopy USA, convertible only upon U.S. stock exchange permissibility for cannabis companies.
• Regulatory Risks:
  • 2025 Canadian Budget: A proposed reduction in medical cannabis reimbursement rates for RCMP and Veterans Affairs Canada (from $8.50 to $6.00/gram) could materially impact medical revenue and margins if passed.
  • Legal Proceedings: The company is subject to an ongoing SEC investigation regarding the BioSteel business unit revenue recognition and several putative class action lawsuits alleging misrepresentations regarding financial disclosures and product costs.

Investor Verification Checklist

• Non-GAAP Reconciliation: Verify the reconciliation of Net Loss to Adjusted EBITDA, noting the exclusion of significant non-cash fair value changes on Canopy USA assets which drove the reported net loss improvement.
• Debt Covenants: Review the terms of the Credit Facility (maturity extended to Sept 2027) and the "Third Paydown Agreement" to ensure compliance with mandatory prepayment schedules.
• Medical Cannabis Exposure: Assess the potential financial impact of the proposed Canadian government reimbursement rate cuts on the medical segment, which contributed $21.8M in Q2 revenue.
• Canopy USA Valuation: Scrutinize the Level 3 fair value inputs used for the Canopy USA LPs investment, as volatility in these assumptions significantly impacts the bottom line.
• Legal Contingencies: Monitor the status of the SEC investigation into BioSteel and the outcomes of the class action lawsuits regarding the Claybourne product launch and Storz & Bickel costs.